Group 1 - AstraZeneca PLC (NASDAQ:AZN) is recognized as one of the Best Low Volatility Investments for December 2025, with a Buy rating maintained by BofA Securities and an increased price target of $108.50 from $91.70 [1] - BofA anticipates critical clinical trial readouts in the next 12 months, particularly for AVANZAR in NSCLC and SERENA-4 in mBC, suggesting attractive upside potential despite investor reservations [2] - On November 21, AstraZeneca announced a $2 billion investment to expand its manufacturing facilities in Maryland, which will enhance production capacity and create 2,600 jobs [3] Group 2 - AstraZeneca is a biopharmaceutical company engaged in the exploration, development, manufacturing, and commercialization of prescription medicines, serving specialty and primary care physicians [4]